Clinical Neuropharmacology
July 31, 2026
Stephen I Deutsch, Jeffrey Elikan, David Spiegel et al.
Last of the Just, a novel of historical fiction published in 16 languages and recipient of France's highest literary award, is recognized for its scholarly contribution to Holocaust education and conceptualization of the Lamid Vavnik, one of "36 (largely anonymous) Just Men of Jewish Tradition" responsible for sustaining humanity. The book's main character is Ernie Levy, who has clinical...
Clinical Neuropharmacology
June 19, 2026
Isabela Heroiu, Gia Han Le, Maria‐christina Sioufi et al.
This systematic review aims to assess the efficacy and tolerability of ketamine in the treatment of obsessive-compulsive disorder. Obsessive-compulsive disorder is a chronic and severe disorder characterized by intrusive thoughts and repetitive behaviours that can cause significant distress. Notwithstanding current treatments and interventions for obsessive-compulsive disorder, some individuals...
Clinical Neuropharmacology
April 1, 2026
Jon E Grant, Sophia Boutouis, Margaret O'Brien et al.
Borderline personality disorder (BPD) is often comorbid with major depressive disorder (MDD), and there has been a suggestion in the literature that this comorbidity may interfere with MDD treatment response. Our objective was to conduct a pilot study of psilocybin in adults with BPD and MDD. Adults aged 18 to 65 years with a DSM-5 diagnosis of MDD and BPD were enrolled in an open-label pilot...
Clinical Neuropharmacology
September 1, 2025
Jaime Moreno‐chaparro, Gabriela Castañeda-millán, Javier Eslava‐schmalbach
3 citations
Objective: Due to the boom in the use of certain psychedelics in different neuropsychiatric conditions, the objective was to synthesize the available information on the use of psilocybin (a psychedelic) in the population with autism spectrum disorder (ASD; a developmental neuropsychiatric condition). Methods: Scoping review. Question framework: Population: people with ASD—Concept:...
Clinical Neuropharmacology
2015
Neil E Paterson, W Connor Darby, Preetpal S Sandhu
N,N-dimethyltryptamine (DMT) is a 5-hydroxytryptamine 2A and 1A receptor agonist that exhibits potent psychoactive properties in humans. Recreational use of this drug has increased precipitously and is likely to result in an increase in patients presenting with substance-induced psychoses. The present case provides an early example of substance-induced psychosis attributable to repeated use of...
Clinical Neuropharmacology
2010
Joshua A Lile, Thomas H Kelly, Lon R Hays
The central effects of Δ-tetrahydrocannabinol (Δ-THC), the primary active constituent of cannabis, are attributed to cannabinoid CB1 receptor activity, although clinical evidence is limited. Drug discrimination has proven useful for examining the neuropharmacology of drugs, as data are concordant with the actions of a drug at the receptor level. The aim of this study was to determine the...
Clinical Neuropharmacology
2009
Massimiliano Aragona, Emanuela Onesti, Valentina Tomassini et al.
To study possible psychopathological symptoms and cognitive deficits, abuse induction, as well as general tolerability and effects on quality of life, fatigue and motor function in cannabis-naïve patients with multiple sclerosis (MS) treated with a free-dose cannabis plant extract (Sativex). In an 8-week, randomized, double-blind, placebo-controlled, parallel group crossover trial, 17...
Clinical Neuropharmacology
April 1, 1996
Meltem Demirkıran, Joseph Jankovic, Joel M. Dean
94 citations
3,4-Methylenedioxymethamphetamine (MDMA), also known as "ecstasy" is a popular recreational drug with potential for abuse. Although its neurotoxic effects have been established in animal studies, the acute and long-term effects of this serotonergic agent in humans are still unknown. We describe a 19-year-old woman with overlapping symptoms of neuroleptic malignant syndrome and serotonin...
Clinical Neuropharmacology
October 1, 1995
Richard B Rosse, John Mastropaolo, D M Sussman et al.
MK-801, a high-affinity phencyclidine (PCP) analogue, is a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptor that elicits hyperactivity, stereotypic behaviors, and "popping," an explosive episodic jumping behavior, in mice. The schizophreniform psychosis precipitated by PCP in humans has stimulated interest in studying MK-801-elicited mouse behaviors...
Clinical Neuropharmacology
June 1, 1995
A L Halberstadt
For the past 20 years, it has been widely assumed that schizophrenia results from chronic dopamine (DA) hyperactivity. However large amounts of evidence exist that call into question this assumption. After examining the brains of schizophrenic patients, studies failed to find evidence of elevated levels of DA, alterations in DA-producing or degrading enzymes or both, or increased DA-receptor...
Clinical Neuropharmacology
August 1, 1994
Richard B Rosse, J P Collins, M Fay-Mccarthy et al.
62 citations
Both stimulant-induced and phencyclidine (PCP)-induced psychoses have been proposed as models of the idiopathic psychosis of schizopherenia. In this two-part study, the phenomenology of the psychosis associated with a period of cocaine intoxication was evaluated retrospectively in 34 male crack cocaine-dependent patients without concomitant psychiatric disorder and then was compared with the...
Clinical Neuropharmacology
June 1, 1993
A Hitri, D A O'Connor, J M Cohen et al.
The ability of phencyclidine (PCP) to model schizophreniform psychosis is believed to be related to its ability to produce both hypoglutamatergia and hyperdopaminergia. As such, identification of PCP-stimulated behaviors may be important for the development of animal models of schizophrenia. In this study, MK-801 [(+)-5-methyl-10,11-dihydro-5H- dibenzo[a,d]cycloheptane-5,10-imine maleate], a...
Clinical Neuropharmacology
1992
Ewa Chojnacka-Wójcik
1 citation
To investigate a possible functional interaction between 5-HT1B and 5-HT1A or 5-HT2 receptors we studied the effects of 5-HT1A selective agonists 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and gepirone, of a 5-HT1A/5-HT2 agonist 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) and of a putative 5-HT2 agonist (+/-)1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane (+/- DOI) on the 5-HT1B...
Clinical Neuropharmacology
October 1, 1991
Juan Sanchez‐ramos
44 citations
It is of historical interest that 63 years ago Louis Lewin reported the use of a hallucinogenic compound prepared from the South American vine, Banisteria Caapi, to treat Parkinson's disease (PD). This psychoactive compound, named banisterine, proved to be identical to harmine, but 30 years were to pass before it was shown to be a reversible monoamine oxidase (MAO) inhibitor. The first reports...
Clinical Neuropharmacology
Wei Xie, Le Wang, Zhe Peng et al.
6 citations
This study aimed to investigate the effects of preoperative low-dose esketamine and dexmedetomidine nasal administration on the incidence of postoperative emergence delirium in children undergoing fiber bronchoscopy. A total of 129 patients, of any gender, aged 1 to 6 years, with ASA grades I and II, who were scheduled for fiber bronchoscopy, were randomly divided into three groups (n = 43)...
Clinical Neuropharmacology
Megan Ralston, Alim Osman, Pavan Suryadevara et al.
4 citations
Ketamine and esketamine have been used in the field of psychiatry to alleviate conditions such as major depressive disorder. Our objective was to evaluate the current literature on the use of ketamine for symptoms of social withdrawal in autism spectrum disorder (ASD) and autism-like conditions. A comprehensive search of PubMed and Web of Science was conducted to identify literature involving...
Clinical Neuropharmacology
Jiancheng Qiu, Yifei Gong, Xiucui Zhang et al.
4 citations
This study was aimed to investigate the effectiveness of mindfulness-based cognitive therapy (MBCT) on depressive symptoms, brain potential, and neuroimmunoinflammatory factors in patients with depression. Sixty-four eligible patients according to the inclusion criteria were randomly divided into the control group and the observation group, with 32 patients in each group. The control group...
Clinical Neuropharmacology
Ramiro Manzano-Nunez, Diego A Gomez, Catalina Toledo-Mendoza et al.
3 citations
This scoping review aimed to synthesize the existing data about psilocybin pharmacokinetics to learn what has been described regarding body disposition and safety when psilocybin was used in controlled research settings. We performed a scoping literature review following the framework proposed by the JBI manual for evidence synthesis. Controlled clinical trials reporting pharmacokinetic data of...
Clinical Neuropharmacology
Megan Jayne Ralston, Alim Osman
1 citation
This study reviews literature on the psychiatric effects of delta-8-THC, particularly psychosis and severe mental health outcomes, to highlight the need for further research and regulation. Marijuana, the most widely used illicit drug in the United States, sees increasing use due to legalization. Although moderate use is generally safe, adverse effects can occur, especially in those with...